Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL.
Leuk Res Rep
; 9: 5-8, 2018.
Article
in En
| MEDLINE
| ID: mdl-29264111
ABSTRACT
â¢Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. â¢We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2 induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic infiltration of the bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem transplantation from his sibling. â¢This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. â¢The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Leuk Res Rep
Year:
2018
Type:
Article
Affiliation country:
United kingdom